Obstetrics, gynaecology & urinary-tract disorder - commissioning policies
Avanafil for erectile dysfunction
Botulinum Toxin for urinary incontinence due to detrusor overactivity
Cryopreservation to Preserve Fertility
Dapoxetine for Premature Ejaculation
Referral for the Surgical Management of Heavy Menstrual Bleeding
Jaydess Levonorgestrel 13.5mg intrauterine system (IUS) for contraception
Tadalafil 5mg tablets (Cialis®) for lower urinary tract symptoms (LUTS) in adult men
Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here
The CCGs’ position on the implementation of policies affecting patient referral can be found here
Safety update: Esmya® (ulipristal acetate)
Ulipristal acetate 5mg tablets (Esmya®) for intermittent treatment of uterine fibroids
Please note in February 2018 the MHRA introduced new temporary safety measures for Esmya® (ulipristal acetate) following reports of serious liver injury in women using the medicine for uterine fibroids.
This advises: do not initiate treatment in new users or those between treatment courses; monitor liver function in current and recent users.
For more information please visit the respective Joint Formulary for South and West Devon and North and East Devon.
Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category.
In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here